Prostate cancer screening: a question of common sense

First results of randomised clinical screening trials are traditionally met with a barrage of comments by opinionated observers, and the back-to-back publication in the March 26 issue of the New England Journal of Medicine on the mortality results of two major PSA screening trials – one European, one American – was no exception. Not only did it reignite the existing controversy but it brought utter confusion to the professional and public media.

Download full article